The pharmacokinetics and pharmacodynamics of irbesartan in heart failure

Journal of Clinical Pharmacology

Volumn 41, Issue 9, 2001, Pages 935-942

  Kostis, J B ^a   Vachharajani, N N ^a   Hadjilambris, O W ^a   Kollia, G D ^a   Palmisano, M ^a   Marino, M R ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; IRBESARTAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE CLASSIFICATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG INFUSION; FATIGUE; FEMALE; HEADACHE; HEART FAILURE; HUMAN; MALE; ORGAN PERFUSION; PLASMA RENIN ACTIVITY; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BIPHENYL COMPOUNDS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HEART FAILURE, CONGESTIVE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0034860983     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122010906     Document Type: Article

References (37)

1. Losartan in heart failure: Preclinical experiences and initial clinical outcomes
2. Guidelines for the evaluation and management of heart failure: Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure)
3. Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure
4. The treatment of heart failure
5. Angiotensin-converting enzyme inhibitors: Mechanisms, pharmacodynamics, and clinical trials in heart failure
6. Angiotensin II-forming pathways in normal and failing human hearts
7. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: A review of the literature and pathophysiology
8. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure
9. The effects of the angiotensin II receptor antagonist irbesartan in patients with congestive heart failure
10. 1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats
11. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
12. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure
13. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial. Losartan Heart Failure Survival Study ELITE II
14. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ace inhibitors, in heart failure
15. Irbesartan compared with lisinopril in patients with mild to moderate heart failure
16. 1 subtype angiotensin II receptor antagonist
17. Effects of the angiotensin II antagonist SR 47436 (BMS 186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects
18. Full antagonism of pressor response to exogenous angiotensin II (AII) by single-dose irbesartan in normotensive subjects
19. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay
20. Efficacy and tolerability of irbesartan, an angiotensin II receptor antagonist, in primary hypertension: A double-blind, placebo-controlled, dose-titration study
21. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension
22. Dose-related efficacy of irbesartan for hypertension: An integrated analysis
23. Safety of irbesartan in the treatment of mild to moderate systemic hypertension
24. Biotransformation of irbesartan in man
25. Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers
26. Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers
27. 1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions
28. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes
29. The effect of age on the pharmacokinetics of irbesartan
30. The effects of age and gender on the pharmacokinetics of irbesartan
31. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis
32. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis
33. Drug-patient interactions and their relevance in the treatment of heart failure
34. Clinical pharmacokinetics in heart failure: An updated review
35. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure
36. Quantitative determination of BMS-186295 in human EDTA plasma
37. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure